MIR4767

Summary

MIR4767 (microRNA 4767, HGNC:41548) is a microRNA gene on chromosome Xp22.31.

microRNAs (miRNAs) are short (20-24 nt) non-coding RNAs that are involved in post-transcriptional regulation of gene expression in multicellular organisms by affecting both the stability and translation of mRNAs. miRNAs are transcribed by RNA polymerase II as part of capped and polyadenylated primary transcripts (pri-miRNAs) that can be either protein-coding or non-coding. The primary transcript is cleaved by the Drosha ribonuclease III enzyme to produce an approximately 70-nt stem-loop precursor miRNA (pre-miRNA), which is further cleaved by the cytoplasmic Dicer ribonuclease to generate the mature miRNA and antisense miRNA star (miRNA*) products. The mature miRNA is incorporated into a RNA-induced silencing complex (RISC), which recognizes target mRNAs through imperfect base pairing with the miRNA and most commonly results in translational inhibition or destabilization of the target mRNA. The RefSeq represents the predicted microRNA stem-loop.

Source: NCBI Gene 100616467 — RefSeq curated summary.

At a glance

• Gene type: non-coding (miRNA) — no protein product; not a drug target. Variant/disease associations are omitted (they would be positional, from an overlapping protein-coding gene).

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:41548
Approved symbol	MIR4767
Name	microRNA 4767
Location	Xp22.31
Locus type	RNA, micro
Status	Approved
Aliases	hsa-mir-4767
Ensembl gene	ENSG00000264268
Ensembl biotype	miRNA
Entrez	100616467
RNAcentral	URS000075C952 — miRNA, 78 nt, 1 organism(s)

Gene structure

Transcript identifiers

Ensembl transcripts: 1 — 1 miRNA

ENST00000582827

RefSeq mRNA: 0 — MANE Select: None

Canonical transcript exons

ENST00000582827 — 1 exons

Exon	Start	End
ENSE00002722038	7147860	7147937

Expression profiles

Bgee: expression breadth broad, 16 present calls, max score 71.27.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 2.8464 / max 55.0547, expressed in 1094 samples.

FANTOM5 promoters (1 alternative TSS)

Promoter ID	TPM avg	Samples expressed
195418	2.8464	1094

Top tissues by expression

16 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
gastrocnemius	UBERON:0001388	71.27	gold quality
minor salivary gland	UBERON:0001830	68.05	gold quality
caudate nucleus	UBERON:0001873	67.98	gold quality
colon	UBERON:0001155	65.65	gold quality
stomach	UBERON:0000945	64.50	gold quality
muscle layer of sigmoid colon	UBERON:0035805	62.55	gold quality
body of stomach	UBERON:0001161	60.50	gold quality
multicellular organism	UBERON:0000468	56.93	gold quality
omental fat pad	UBERON:0010414	56.85	gold quality
lower esophagus muscularis layer	UBERON:0035833	56.15	gold quality
left lobe of thyroid gland	UBERON:0001120	52.32	gold quality
tibial nerve	UBERON:0001323	50.26	gold quality
liver	UBERON:0002107	48.64	gold quality
spleen	UBERON:0002106	43.04	silver quality
left testis	UBERON:0004533	35.92	gold quality
skin of abdomen	UBERON:0001416	34.48	silver quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 0.

Experiment	Marker?	Max mean expression
E-ANND-3	no	1.17

Regulation

Is transcription factor: no

Literature-anchored findings (GeneRIF, showing 3)

• Study provides evidence that Long Noncoding RNA LOC100129973 suppresses apoptosis by targeting miR-4707-5p and miR-4767 in vascular endothelial cells. (PMID:26887505)
• our study provides evidence that miR-4756 accelerates the process of diabetic kidney disease (DKD) through Sestrin2, suggesting that targeting miR-4756 may be a novel strategy for DKD treatment. (PMID:30145827)
• LINC00858 promotes colorectal cancer by sponging miR-4766-5p to regulate PAK2. (PMID:31902050)

Cross-species orthologs

0 orthologs

Protein

Non-coding RNA — no protein product; not a drug target.

Function

No curated pathway, Gene-Ontology, or interaction data.

Disease & clinical

No curated disease, variant, or cancer-driver associations.

Drugs & pharmacology

No drug or pharmacology data — not an established drug target.